Pharmacy-related buprenorphine access barriers: an audit of pharmacies in counties with a high opioid overdose burden - Kazerouni NJ, Irwin AN, Levander XA, Geddes J, Johnston K, Gostanian CJ, Mayfield BS, Montgomery BT, Graalum DC, Hartung DM.
The objective of this study was to quantify the frequency of barriers encountered by patients seeking to fill buprenorphine... (Source: SafetyLit)
Source: SafetyLit - May 4, 2021 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

One in five pharmacies blocks access to key medication to treat addiction
(Oregon Health& Science University) One out of five pharmacies refuse to dispense a key medication to treat addiction, according to an audit of hundreds of pharmacies nationwide. Researchers found found that independent pharmacies and those in southern U.S. states were significantly more likely to restrict access to buprenorphine, also known as Suboxone. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 26, 2021 Category: International Medicine & Public Health Source Type: news

Cassipa (Buprenorphine and Naloxone Sublingual Film) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 29, 2021 Category: Drugs & Pharmacology Source Type: news

Hudson Woman Sentenced to 15 Months for Tampering with Consumer Products and Unlawfully Obtaining Controlled Substances
FDA OCI, Kristina Coleman, Hudson NH, sentence, tampering, opioid, pharmacy technician, Nashua, oxycodone, baclofen, suboxone, muscle relaxant, replacement, controlled substance, (Source: Office of Criminal Investigations (OCI) Press Releases)
Source: Office of Criminal Investigations (OCI) Press Releases - March 2, 2021 Category: Medical Law Authors: DOJ Source Type: news

Patient, prescriber, and community factors associated with filled naloxone prescriptions among patients receiving buprenorphine 2017-18 - Stein BD, Jones CM, Smart R, Sheng F, Sorbero M.
BACKGROUND: Prescribing naloxone to patients at increased opioid overdose risk is a key component of opioid overdose prevention efforts, but little is known about naloxone fills among patients receiving buprenorphine for opioid use disorder, one such high ... (Source: SafetyLit)
Source: SafetyLit - February 15, 2021 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

International Prehospital Medicine Institute Literature Review, January 2021
This study compares the 10-g AC to the 14-g AC for decompression of a tPTX and rescue from a tension-induced pulseless electrical activity (tPEA) in the setting of 30% estimated blood volume loss without hemothorax. The authors hypothesized the 10-g AC would be more effective and have a faster rescue from tension physiology than the 14-g AC currently used by most EMS systems. This was an animal study utilizing anesthetized pigs. The researchers placed arterial and venous lines for hemodynamic monitoring. They then placed 12-mm trocars through each diaphragm through which they could infuse carbon dioxide to simulate a te...
Source: JEMS Patient Care - January 1, 2021 Category: Emergency Medicine Authors: JEMS Staff Tags: Exclusives International Prehospital Medicine Institute Source Type: news

International Prehospital Medicine Institute Literature Review, January 2021
This study compares the 10-g AC to the 14-g AC for decompression of a tPTX and rescue from a tension-induced pulseless electrical activity (tPEA) in the setting of 30% estimated blood volume loss without hemothorax. The authors hypothesized the 10-g AC would be more effective and have a faster rescue from tension physiology than the 14-g AC currently used by most EMS systems. This was an animal study utilizing anesthetized pigs. The researchers placed arterial and venous lines for hemodynamic monitoring. They then placed 12-mm trocars through each diaphragm through which they could infuse carbon dioxide to simulate a te...
Source: JEMS Administration and Leadership - January 1, 2021 Category: Emergency Medicine Authors: JEMS Staff Tags: Exclusives International Prehospital Medicine Institute Source Type: news

International Prehospital Medicine Institute Literature Review, January 2021
This study compares the 10-g AC to the 14-g AC for decompression of a tPTX and rescue from a tension-induced pulseless electrical activity (tPEA) in the setting of 30% estimated blood volume loss without hemothorax. The authors hypothesized the 10-g AC would be more effective and have a faster rescue from tension physiology than the 14-g AC currently used by most EMS systems. This was an animal study utilizing anesthetized pigs. The researchers placed arterial and venous lines for hemodynamic monitoring. They then placed 12-mm trocars through each diaphragm through which they could infuse carbon dioxide to simulate a te...
Source: JEMS: Journal of Emergency Medical Services News - January 1, 2021 Category: Emergency Medicine Authors: JEMS Staff Tags: Exclusives International Prehospital Medicine Institute Source Type: news

International Prehospital Medicine Institute Literature Review, January 2021
This study compares the 10-g AC to the 14-g AC for decompression of a tPTX and rescue from a tension-induced pulseless electrical activity (tPEA) in the setting of 30% estimated blood volume loss without hemothorax. The authors hypothesized the 10-g AC would be more effective and have a faster rescue from tension physiology than the 14-g AC currently used by most EMS systems. This was an animal study utilizing anesthetized pigs. The researchers placed arterial and venous lines for hemodynamic monitoring. They then placed 12-mm trocars through each diaphragm through which they could infuse carbon dioxide to simulate a te...
Source: JEMS Operations - January 1, 2021 Category: Emergency Medicine Authors: JEMS Staff Tags: Exclusives International Prehospital Medicine Institute Source Type: news

International Prehospital Medicine Institute Literature Review, January 2021
This study compares the 10-g AC to the 14-g AC for decompression of a tPTX and rescue from a tension-induced pulseless electrical activity (tPEA) in the setting of 30% estimated blood volume loss without hemothorax. The authors hypothesized the 10-g AC would be more effective and have a faster rescue from tension physiology than the 14-g AC currently used by most EMS systems. This was an animal study utilizing anesthetized pigs. The researchers placed arterial and venous lines for hemodynamic monitoring. They then placed 12-mm trocars through each diaphragm through which they could infuse carbon dioxide to simulate a te...
Source: JEMS Special Topics - January 1, 2021 Category: Emergency Medicine Authors: JEMS Staff Tags: Exclusives International Prehospital Medicine Institute Source Type: news

International Prehospital Medicine Institute Literature Review, January 2021
This study compares the 10-g AC to the 14-g AC for decompression of a tPTX and rescue from a tension-induced pulseless electrical activity (tPEA) in the setting of 30% estimated blood volume loss without hemothorax. The authors hypothesized the 10-g AC would be more effective and have a faster rescue from tension physiology than the 14-g AC currently used by most EMS systems. This was an animal study utilizing anesthetized pigs. The researchers placed arterial and venous lines for hemodynamic monitoring. They then placed 12-mm trocars through each diaphragm through which they could infuse carbon dioxide to simulate a te...
Source: JEMS Latest News - January 1, 2021 Category: Emergency Medicine Authors: JEMS Staff Tags: Exclusives International Prehospital Medicine Institute Source Type: news

An alternative analysis of illicit opioid use during treatment in a randomized trial of extended-release naltrexone versus buprenorphine-naloxone: a per-protocol and completers analysis - Mitchell MM, Schwartz RP, Choo TH, Pavlicova M, O'Grady KE, Gryczynski J, Stitzer ML, Nunes EV, Rotrosen J.
BACKGROUND: The distinct pharmacological properties and clinical uses of extended-release naltrexone (XR-NTX) and sublingual buprenorphine-naloxone (BUP-NX) present challenges in analyzing patient outcomes. METHODS: We conducted a secondary analysis of... (Source: SafetyLit)
Source: SafetyLit - December 25, 2020 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Former Medical Director of Suboxone Manufacturer Indivior Sentenced in Connection with Drug Safety Claims
FDA OCI, Suboxone Film, Indivior, medical director, sentence, drug safety, claims, Timothy Baxter, marketing, opioid, drug, Massachusetts Medicaid, recovering addicts, misbranded drug, MassHealth, false, misleading, information, accidental, pediatric, exposure, (Source: Office of Criminal Investigations (OCI) Press Releases)
Source: Office of Criminal Investigations (OCI) Press Releases - December 18, 2020 Category: Medical Law Authors: DOJ Source Type: news

Reckitt Benckiser files £1bn claim against former subsidiary Indivior
Claim relates to US settlement over past marketing of opioid addiction treatment Suboxone (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - November 27, 2020 Category: Pharmaceuticals Source Type: news

Indivior Solutions Sentenced as Part of $2 Billion Resolution of False Safety Claims Concerning Suboxone
FDA OCI, Indivior, Suboxone, sentence, $2 billion restitution, false safety claims, criminal penalties marketing, false statements, health care, sales force, disbanded, Shaun Thaxter, Tim Baxter, misleading data, false data, pediatric exposure, prison sentence, CEO, MassHealth, Reckitt Benckiser, (Source: Office of Criminal Investigations (OCI) Press Releases)
Source: Office of Criminal Investigations (OCI) Press Releases - November 17, 2020 Category: Medical Law Authors: DOJ Source Type: news

Suboxone Manufacturer Indivior's Former Chief Executive Officer Sentenced to Jail Time in Connection with Drug Safety Claims
FDA OCI, Suboxone, CEO, Indivior, CEO, sentence, jail, drug safety claims, Shaun Thaxter, 6 months jail, misbranded drug, Suboxone Film, Reckitt Benckiser, opioid, buprenorphine, addiction treatment, false, misleading, safety information, (Source: Office of Criminal Investigations (OCI) Press Releases)
Source: Office of Criminal Investigations (OCI) Press Releases - October 27, 2020 Category: Medical Law Authors: DOJ Source Type: news

Hudson Woman Pleads Guilty to Tampering with Consumer Products and Unlawfully Obtaining Controlled Substances
FDA OCI, Kristina Coleman, Hudson NH, tampering, pharmacy technician, Nashua NH, prescription delivery, missing pills, oxycodone, opioids, different sizes, different imprints, baclofen, Suboxone, theft, (Source: Office of Criminal Investigations (OCI) Press Releases)
Source: Office of Criminal Investigations (OCI) Press Releases - October 21, 2020 Category: Medical Law Authors: DOJ Source Type: news

Opioid Manufacturer Indivior ’s Former Global Medical Director Pleads Guilty in Connection with Drug Safety Claims
FDA OCI, opioid, Indivior, director, guilty plea, drug safety claims, Timothy BAXTER, Suboxone Film, misdemeanor, misbranded drug, top medical executive, Reckitt Benckiser Pharmaceuticals, global medical director, $600 million, criminal liability, civil liability, opioid recovery, (Source: Office of Criminal Investigations (OCI) Press Releases)
Source: Office of Criminal Investigations (OCI) Press Releases - September 8, 2020 Category: Medical Law Authors: DOJ Source Type: news

Indivior Solutions Pleads Guilty to Felony Charge and Indivior Entities Agree to Pay $600 Million to Resolve Criminal and Civil Investigations as Part of DOJ ’s Largest Opioid Resolution
FDA OCI, Indivior, Suboxone, film, felony, opioid, resolution, $600 million, resolve, criminal liability, civil liability, opioid, addiction, treatment, $1.4 billion, , Reckitt Benckiser, largest, withdrawal, buprenorphine, powerful opioid, film, tablet, (Source: Office of Criminal Investigations (OCI) Press Releases)
Source: Office of Criminal Investigations (OCI) Press Releases - July 28, 2020 Category: Medical Law Authors: DOJ Source Type: news

Indivior pays $600m in US opioid settlement
Resolution with justice department takes total paid over addiction treatment Suboxone to $2bn (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - July 24, 2020 Category: Pharmaceuticals Source Type: news

FDA: Doctors Should Discuss Opioid OD Antidote With Patients
FRIDAY, July 24, 2020 -- Doctors should tell patients and caregivers about the overdose antidote naloxone when they prescribe opioid painkillers such as Percocet and OxyContin and medicines to treat opioid addiction, including buprenorphine,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 24, 2020 Category: Pharmaceuticals Source Type: news

Opioid Manufacturer Indivior ’s Chief Executive Officer Pleads Guilty in Connection with Drug Safety Claims
FDA OCI, Shaun Thaxter, CEO, Indivior, guilty plea, opioid, Suboxone Film, misbranded, Reckitt Benckiser, recovery, addicts, marketing, withdrawal, treatment, buprenorphine, sales, preferred drug status, false information, misleading information (Source: Office of Criminal Investigations (OCI) Press Releases)
Source: Office of Criminal Investigations (OCI) Press Releases - July 1, 2020 Category: Medical Law Authors: DOJ Source Type: news

Depression history as a predictor of outcomes during buprenorphine-naloxone treatment of prescription opioid use disorder - Peckham AD, Griffin ML, McHugh RK, Weiss RD.
BACKGROUND: In the multi-site Prescription Opioid Addiction Treatment Study (POATS), the best predictor of successful opioid use outcome was lifetime diagnosis of major depressive disorder. The primary aim of this secondary analysis of data from POATS was ... (Source: SafetyLit)
Source: SafetyLit - June 24, 2020 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Baymark Health Services Acquires Two Suboxone Clinics In Louisiana
BayMark brand AppleGate Recovery expands footprint and enhances opioid addiction treatment services.(PRWeb May 15, 2020)Read the full story at https://www.prweb.com/releases/baymark_health_services_acquires_two_suboxone_clinics_in_louisiana/prweb17124788.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 15, 2020 Category: Pharmaceuticals Source Type: news

Willingness to take buprenorphine/naloxone among people who use opioids in Vancouver, Canada - Weicker SA, Hayashi K, Grant C, Milloy MJ, Wood E, Kerr T.
OBJECTIVES: Opioid agonist therapy is the cornerstone of treatment of opioid use disorder. In Canada, buprenorphine/naloxone has recently been adopted as the first line agonist therapy given its comparable effectiveness to methadone and superior safety pro... (Source: SafetyLit)
Source: SafetyLit - November 16, 2019 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Five Pennsylvania Physicians Charged with Unlawfully Distributing Buprenorphine and Defrauding Medicare and Medicaid
opioid addiction treatment, Krishan Kumar Aggarwal, Moon Township PA, RTA, Weirton WV, Madhu Aggarwal, Bridgeville PA, Parth Bharill, Pittsburgh PA, Cherian John, Coraopolis PA, Weirton WV, Michael Bummer, Sewickley PA, Suboxone, buprenorphine, Subutex, Redirections Treatment Advocates, (Source: Office of Criminal Investigations (OCI) Press Releases)
Source: Office of Criminal Investigations (OCI) Press Releases - October 23, 2019 Category: Medical Law Authors: DOJ Source Type: news

Association between buprenorphine/naloxone and high-dose opioid analgesic prescribing in Kentucky, 2012-2017 - Luu H, Slavova S, Freeman PR, Lofwall M, Browning S, Slade E, Bush H.
INTRODUCTION: Buprenorphine/naloxone treatment is a highly effective treatment for opioid use disorder decreasing illicit opioid use and both all-cause and opioid-involved overdose mortality. The purpose of this study was to investigate the relationships b... (Source: SafetyLit)
Source: SafetyLit - October 16, 2019 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Embattled drugmaker Indivior raises forecasts on Suboxone strength
Indivior Plc on Tuesday raised its full-year forecasts as the embattled British drugmaker's best-selling opioid addiction drug Suboxone fared better than expected in the face of competition from copycats. (Source: Reuters: Health)
Source: Reuters: Health - October 15, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Indivior shares rise as it boosts guidance for a second time
Drugmaker lifted by strong performance of opioid treatment Suboxone (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - October 15, 2019 Category: Pharmaceuticals Source Type: news

Justice Department Obtains $1.4 Billion from Reckitt Benckiser Group in Largest Recovery in a Case Concerning an Opioid Drug in United States History
Suboxone, recovering opioid addicts, withdrawal symptoms, buprenorphine, Individor, Suboxone Film, Here to Help, discontinuance of tablet Suboxone, (Source: Office of Criminal Investigations (OCI) Press Releases)
Source: Office of Criminal Investigations (OCI) Press Releases - August 8, 2019 Category: Medical Law Authors: DOJ Source Type: news

MedicaSafe Turns Attention to Opioid Addiction
One of MedicaSafe’s primary goals is to develop products for high-risk medication management. So it makes sense for the New York-based company to focus on opioid addiction, which claims the lives of more than 130 people every day in the U.S. (According to the U.S. Department of Health and Human Services). The New York-based company recently received $1 million Small Business Innovation Research grant from the National Institute of Health, with a specific focus on opioid use disorder (OUD). The funding will support a clinical trial to examine the effect of MedicaSafe’s drug-device combina...
Source: MDDI - July 19, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Digital Health Source Type: news

Indivior loses appeal to block generic Suboxone opioid treatments
A divided federal appeals court on Friday ruled against Indivior Plc in its bid to stop Dr. Reddy's Laboratories Ltd and Alvogen from selling generic versions of its opioid addiction treatment Suboxone film that infringed its patents. (Source: Reuters: Health)
Source: Reuters: Health - July 12, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Reckitt to pay $1.4B in opioid settlement
Reckitt Benckiser Group will pay up to $1.4 billion to settle U.S. investigations into whether its former pharma unit organized a multibillion-dollar fraud to drive up sales of its opioid-addiction treatment, Suboxone. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 12, 2019 Category: Pharmaceuticals Source Type: news

Indivior raises guidance on strong performance of opioid treatment
Suboxone drug has been at the centre of a US probe into its marketing (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - July 11, 2019 Category: Pharmaceuticals Source Type: news

New Jersey Authorizes Paramedics to Carry Buprenorphine
TRENTON (Cape May County Herald) - The State Health Commissioner June 24 authorized paramedics to carry buprenorphine to treat acute withdrawal symptoms after patients have been revived from an opioid overdose with Naloxone, the opioid overdose reversal drug. According to a release, Commissioner Dr. Shereef Elnahal signed an Executive Directive on that date allowing the medical directors of New Jersey’s 21 Mobile Intensive Care Unit (MICU) programs to authorize paramedics to carry buprenorphine, an oral medication used to mitigate what can be severe symptoms of opioid withdrawal after a Naloxone reversal. The MICU pr...
Source: JEMS: Journal of Emergency Medical Services News - July 3, 2019 Category: Emergency Medicine Tags: News Patient Care Administration and Leadership Source Type: news

New Jersey Authorizes Paramedics to Carry Buprenorphine
TRENTON (Cape May County Herald) - The State Health Commissioner June 24 authorized paramedics to carry buprenorphine to treat acute withdrawal symptoms after patients have been revived from an opioid overdose with Naloxone, the opioid overdose reversal drug. According to a release, Commissioner Dr. Shereef Elnahal signed an Executive Directive on that date allowing the medical directors of New Jersey’s 21 Mobile Intensive Care Unit (MICU) programs to authorize paramedics to carry buprenorphine, an oral medication used to mitigate what can be severe symptoms of opioid withdrawal after a Naloxone reversal. The MICU pr...
Source: JEMS Patient Care - July 3, 2019 Category: Emergency Medicine Tags: News Patient Care Administration and Leadership Source Type: news

Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids - Barocas JA, Morgan JR, Fiellin DA, Schackman BR, Eftekhari Yazdi G, Stein MD, Freedberg KA, Linas BP.
BACKGROUND: Untreated opioid use disorder (OUD) affects the care of HIV/HCV co-infected people who inject opioids. Despite active injection opioid use, there is evidence of increasing engagement in HIV care and adherence to HIV medications among HIV/HCV co... (Source: SafetyLit)
Source: SafetyLit - May 17, 2019 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Indivior shares plummet, Reckitt hurt on U.S. charges over opioid prescriptions
British drugmaker Indivior Plc lost nearly three-quarters of its share value on Wednesday and former parent Reckitt Benckiser also fell following U.S. criminal charges accusing Indivior of illegally increasing prescriptions for its opioid addiction treatment Suboxone. (Source: Reuters: Health)
Source: Reuters: Health - April 10, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

DOJ charges UK drugmaker with Suboxone fraud
Federal prosecutors with the Department of Justice have indicted Indivior for what they call a multibillion-dollar scheme to ratchet up sales of an opioid addiction treatment. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - April 10, 2019 Category: Pharmaceuticals Source Type: news

Anti-opioid addiction drug maker charged with fraud
Federal prosecutors in Virginia say the company that makes a Suboxone strips to curb opioid addiction has been lying for years about the relative safety of its product (Source: ABC News: Health)
Source: ABC News: Health - April 10, 2019 Category: Consumer Health News Tags: Health Source Type: news

Indivior shares tank after U.S. indictment for illegal marketing
Shares of Indivior Plc sank 44 percent on Wednesday after the U.S. Justice Department accused the British drugmaker of illegally boosting prescriptions for the film version of its blockbuster opioid addiction treatment Suboxone. (Source: Reuters: Health)
Source: Reuters: Health - April 10, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

U.S. indicts Indivior over Suboxone opioid treatment marketing
The U.S. Justice Department announced on Tuesday the indictment of Indivior Plc and a subsidiary on charges they engaged in an illegal scheme to boost prescriptions of the film version of its opioid addiction treatment Suboxone. (Source: Reuters: Health)
Source: Reuters: Health - April 10, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

New Buprenorphine and Naloxone Sublingual Film Indicated for The Treatment of Opioid Dependence
FDA approved Buprenorphine and Naloxone Sublingual film are available in 8 mg/2 mg and 12 mg/3 mg The prescription is limited to healthcare providers who meet certain qualifying requirements Should be used as part of a complete treatment plan to include counseling and psychosocial supportThis story is related to the following:Medicinal, Pharmaceutical& Nutraceutical Tablets (Source: Industrial Newsroom - Health, Medical and Dental Supplies)
Source: Industrial Newsroom - Health, Medical and Dental Supplies - February 25, 2019 Category: Medical Devices Source Type: news

Mylan Launches Generic Suboxone(R) Sublingual Film to Treat Opioid Dependence
HERTFORDSHIRE, England and PITTSBURGH, Feb. 22, 2019 -- (Healthcare Sales & Marketing Network) -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Buprenorphine and Naloxone Sublingual Film, 8 mg/2 mg and 12 mg/3 m... Biopharmaceuticals, Drug Delivery, Generics, Product Launch Mylan, Buprenorphine, Naloxone, Suboxone, Sublingual (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 22, 2019 Category: Pharmaceuticals Source Type: news

Mylan launches generic sublingual film for opioid dependence
Mylan (NSDQ:MYL) said today that it launched its buprenorphine and naloxone sublingual film as a generic of Indivior‘s (LON:INDV) Suboxone sublingual film. The product is indicated for the treatment of opioid dependence. The therapy should be used alongside counseling and psychosocial support for people living with opioid dependence, according to Mylan. Get the full story at our sister site, Drug Delivery Business News. The post Mylan launches generic sublingual film for opioid dependence appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - February 22, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Business/Financial News Drug-Device Combinations Featured Pharmaceuticals Wall Street Beat Dr. Reddy's Laboratories indivior Mylan Source Type: news

Indivior launches generic version of its Suboxone opioid drug
British drugmaker Indivior Plc said on Wednesday it had launched a copycat version of its blockbuster opioid addiction drug Suboxone in the United States, just one day after a court decision cleared the way for its rivals to market generic versions of it. (Source: Reuters: Health)
Source: Reuters: Health - February 20, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

U.S. top court rejects bid to block Indivior opioid drug copycat
The U.S. Supreme Court dealt a blow to Indivior Plc on Tuesday, clearing the way for a copycat version of the British pharmaceutical firm's lucrative opioid addiction treatment Suboxone Film in a victory for India-based generic drug maker Dr. Reddy's Laboratories. (Source: Reuters: Health)
Source: Reuters: Health - February 19, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Overdose patients at Vancouver hospital to get take-home opioid medication
Touted as a first for Canadian emergency departments, physicians at St. Paul's Hospital in Vancouver will send overdose victims home with enough Suboxone for three days of treatment. (Source: CBC | Health)
Source: CBC | Health - February 7, 2019 Category: Consumer Health News Tags: News/Canada/British Columbia Source Type: news

'I feel normal': health officials eye injectable opioid addiction treatment
Sublocade, an injectable alternative to Suboxone, has been approved by Health Canada after a successful run in the U.S. The treatment is administered once a month and is highly touted by many American physicians. (Source: CBC | Health)
Source: CBC | Health - January 17, 2019 Category: Consumer Health News Tags: News/Canada/British Columbia Source Type: news